Topical ocular TRPV1 antagonist SAF312 was well tolerated and effectively reduced pain after photorefractive keratectomy (PRK)

被引：0

作者：

Stasi, Kalliopi ^{[1
]}

Thompson, Vance ^{[2
]}

Moshirfar, Wjid ^{[3
]}

Clinch, Thomas ^{[4
]}

Scoper, Stephen ^{[5
]}

Linn, Steven ^{[3
]}

McIntosh, Avery ^{[1
]}

Li, Yifang ^{[1
]}

Eaton, Matt ^{[1
]}

Palmer, Michela Montecchi ^{[6
]}

Haque, Sameena ^{[7
]}

Ferriere, Michael ^{[1
]}

机构：

[1] Novartis Inst Biomed Res, Cambridge, MA USA

[2] Vance Thompson Vis, Sioux Falls, SD USA

[3] Hoopes Vis Res Ctr, Draper, UT USA

[4] Eye Doctors Washington, Washington, DC USA

[5] Virginia Eye Consultants, Norfolk, VA USA

[6] Novartis Pharmaceut Inc, Ft Worth, TX USA

[7] Novartis Pharma AG, Basel, Switzerland

来源：

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2021年 / 62卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

967

引用

页数：3

共 6 条

[1] Topical Ocular TRPV1 Antagonist SAF312 (Libvatrep) for Postoperative Pain After Photorefractive Keratectomy
Thompson, Vance
Moshirfar, Majid
Clinch, Thomas
Scoper, Stephen
Linn, Steven H.
McIntosh, Avery
Li, Yifang
Eaton, Matt
Ferriere, Michael
Stasi, Kalliopi
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2023, 12 (03):
[2] Ocular Pharmacology and Toxicology of TRPV1 Antagonist SAF312 (Libvatrep)
Mogi, Muneto
Mendonza, Anisha E.
Chastain, James
Demirs, John T.
Medley, Quintus G.
Zhang, Qin
Papillon, Julien P. N.
Yang, Junzheng
Gao, Yan
Xu, YongYao
Stasi, Kalliopi
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2023, 12 (09):
[3] Topical ocular TRPV1 antagonist SAF312 demonstrated safety, low systemic exposure, and no anesthetic effect in healthy volunteers
Li, Yifang
Jain, Monish
Palmer, Michela
Haque, Sameena
Stasi, Kalliopi
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
[4] Topical Ocular TRPV1 Antagonist SAF312 (Libvatrep) Demonstrates Safety, Low Systemic Exposure, and No Anesthetic Effect in Healthy Participants
Stasi, Kalliopi
Alshare, Qusai
Jain, Monish
Wald, Michael
Li, Yifang
TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2022, 11 (01):
[5] SAFETY, TOLBERABILITY AND PHARMACOKINETICS OF MULTIPLE DOSES OF THE TRPV1 ANTAGONIST SAF312 IN HEALTHY SUBJECTS
Schramm, U.
Vaidya, S.
Tavares, G.
Roberts, J.
Francke, K.
El Mouelhi, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S68 - S69
[6] SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE DOSES OF THE TRPV1 ANTAGONIST SAF312 IN HEALTHY SUBJECTS
El Mouelhi, M.
Bartlett, M.
Roberts, J.
Vaidya, S.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S68 - S68

← 1 →